Hwail Pharmaceutical Co.Ltd (061250) Fair Value & Analysis
Healthcare · KR · Market cap 72.6B KRW
Strengths
Risks
Fair value as of: Aug 19, 2026
From 7 valuation models · updated 2 days ago
Share price −11.9% over the past month.
A solid business, screening 145% undervalued on our models.
What matters now
- The price is below even our cautious bear case (15,825 KRW). The market is more pessimistic than our downside scenario.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid quality (57/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 19, 2026.
How to read this chart
60‑month range 7,410 KRW – 53,900 KRW · fair‑value band 15,825 KRW – 23,130 KRW · the 7,940 KRW price screens below the 19,477 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 19, 2026.
Analysis
Hwail Pharmaceutical Co.Ltd (061250) currently trades at 7,940 KRW, while our model-based Fair Value estimate is 19,477 KRW, implying the stock looks roughly 145.3% undervalued today. The Quality Score stands at 57/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Hwail Pharmaceutical Co.Ltd generated revenue of 108B KRW at a net margin of 1.8%. Revenue declined 11.6% year over year. It earns a return on equity of 1.9%. Fundamentals as of Aug 19, 2026
Our scenario range runs from 15,825 KRW (bear case) to 23,130 KRW (bull case); at 7,940 KRW, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 42% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -40% fair-value upside, at 145%, 061250 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 7 models by family
Widest divergence: Growth DCF (19,579 KRW) versus Asset-Based (16,466 KRW). Highest evidence: Growth DCF (80).
Notify me when 061250 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 58 · Market factors (momentum, volatility) 34
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Hwail Pharmaceutical Co.,Ltd. develops pharmaceutical raw materials in South Korea. It provides raw drug products, finished drug products, and functional health food raw material business. The company was founded in 1974 and is headquartered in Seongnam-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Hwail Pharmaceutical Co.Ltd reported revenue of 101B KRW in FY2025 versus 107B KRW in FY2021, a compound −1.5%/yr. Reported net income was −233M KRW in FY2025.
Watch 061250: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 638 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$56.05 | HK$33.59 | -40% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹8,525 | ₹1,228 | -86% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,915 | ₹1,163 | -76% |
| PharmaEssentia Corporation 6446 | 1,440 TWD | 233.93 TWD | -84% |
| Cipla Limited CIPLA | ₹1,463 | ₹1,001 | -32% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,167 | ₹703.32 | -40% |
| Lupin Limited LUPIN | ₹2,281 | ₹2,477 | +9% |
| Mankind Pharma Limited MANKIND | ₹2,433 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,200 | ₹874.79 | -27% |
Compare Hwail Pharmaceutical Co.Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Hwail Pharmaceutical Co.Ltd (061250) overvalued or undervalued?
What is the fair value of 061250?
What is the quality score of 061250?
What is the revenue of Hwail Pharmaceutical Co.Ltd (061250)?
What is the net profit margin of 061250?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Hwail Pharmaceutical Co.Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.